[Form 4] Theravance Biopharma, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Brett A. Grimaud, SVP, General Counsel and Secretary of Theravance Biopharma, reported a transaction on Form 4. On 08/20/2025 he disposed of 9,762 ordinary shares at an average price of $13.39 per share. The filing states the shares were withheld to satisfy tax obligations arising from the vesting of previously granted restricted stock units; the withholding was executed with the issuer and was not an open-market sale. After the transaction he beneficially owned 374,306 shares (direct). The Form 4 is signed 08/22/2025.

Insights

Corporate Governance Expert

TL;DR: Routine tax withholding on vested RSUs; non-market transfer preserves insider alignment with shareholders.

The Form 4 documents a common post-vesting tax withholding rather than a discretionary open-market sale. Because the withholding was administered by the issuer, it typically indicates compliance with compensation tax obligations and does not reflect active liquidity-seeking by the officer. The reporting person retains substantial direct ownership of 374,306 shares, suggesting continued alignment with shareholders.

Securities Analyst

TL;DR: Small disposition relative to total holdings; transaction is operationally routine and unlikely to affect market perception.

The disposed amount of 9,762 shares at $13.39 appears limited in size relative to the remaining beneficial holding. The explicit explanation—share withholding for taxes on vested RSUs—matches standard insider compensation mechanics and provides transparency on the nature and price of the transfer.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grimaud Brett A.

(Last) (First) (Middle)

C/O THERAVANCE BIOPHARMA US, LLC

901 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, GEN COUNSEL AND SECRETARY

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/20/2025		F		9,762(1)	D	$13.39	374,306	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

	/s/ Brett A. Grimaud	08/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Brett A. Grimaud report on Form 4 for TBPH?

He reported a disposition of 9,762 ordinary shares on 08/20/2025 at $13.39 per share, executed as share withholding to cover taxes from vested RSUs.

Was the share disposition an open-market sale?

No. The filing states the share withholding transaction was with the issuer and did not involve an open-market transaction.

How many TBPH shares does the reporting person own after the transaction?

After the reported transaction the reporting person beneficially owned 374,306 shares (direct).

What is the relationship of the reporting person to Theravance Biopharma (TBPH)?

Brett A. Grimaud is an Officer (SVP, General Counsel and Secretary) and is also listed as a Director on the Form 4.

When was the Form 4 signed?

The Form 4 bears the reporting person's signature dated 08/22/2025.